Haemoglobin E disease (Q39522): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed an Item |
||||||||||||||
| (7 intermediate revisions by the same user not shown) | |||||||||||||||
| description / pt-br | description / pt-br | ||||||||||||||
Doença da hemoglobina E é caracterizada pela síntese de uma hemoglobina anormal chamada hemoglobina E (Hb E), em vez da hemoglobina A normal (Hb A). Indivíduos heterozigotos para Hb E (AE) têm uma condição assintomática sem relevância clínica, exceto pelo risco de transmitir talassemia E/beta talassemia se o outro progenitor for portador da beta talassemia. A gravidade destas formas de E/beta talassemia é muito variável, e o quadro clínico varia daquela do traço da talassemia minor até talassemia intermédia e talassemia maior. Os indivíduos homozigotos para Hb E (EE) são assintomáticos. | |||||||||||||||
| description / en | description / en | ||||||||||||||
Haemoglobin E disease is characterised by the synthesis of an abnormal haemoglobin called haemoglobin E (HbE), instead of the normal haemoglobin A (HbA). Subjects heterozygous for HbE (AE) have an asymptomatic condition with no clinical relevance, except for the risk of transmitting E/beta thalassemia if the other parent carries beta thalassemia. The severity of these E/beta thalassemia forms is very variable, the clinical picture ranging from that of beta thalassemia minor through to thalassemia intermedia to thalassemia major. Subjects homozygous for HbE (EE) are asymptomatic. | |||||||||||||||
| Property / Canonical URI | |||||||||||||||
| Property / Canonical URI: https://id.who.int/icd/entity/1898135714 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / CURIE | |||||||||||||||
CID11:3A51.A | |||||||||||||||
| Property / CURIE: CID11:3A51.A / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Canary Token | |||||||||||||||
dki-india-3A51.A | |||||||||||||||
| Property / Canary Token: dki-india-3A51.A / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Verification Status | |||||||||||||||
Concluído | |||||||||||||||
| Property / Verification Status: Concluído / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Linked ICD 10 | |||||||||||||||
| Property / Linked ICD 10: D57 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 04:58, 13 August 2026
Haemoglobin E disease is characterised by the synthesis of an abnormal haemoglobin called haemoglobin E (HbE), instead of the normal haemoglobin A (HbA). Subjects heterozygous for HbE (AE) have an asymptomatic condition with no clinical relevance, except for the risk of transmitting E/beta thalassemia if the other parent carries beta thalassemia. The severity of these E/beta thalassemia forms is very variable, the clinical picture ranging from that of beta thalassemia minor through to thalassemia intermedia to thalassemia major. Subjects homozygous for HbE (EE) are asymptomatic.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | 3A51.A |
||
| English | Haemoglobin E disease |
Haemoglobin E disease is characterised by the synthesis of an abnormal haemoglobin called haemoglobin E (HbE), instead of the normal haemoglobin A (HbA). Subjects heterozygous for HbE (AE) have an asymptomatic condition with no clinical relevance, except for the risk of transmitting E/beta thalassemia if the other parent carries beta thalassemia. The severity of these E/beta thalassemia forms is very variable, the clinical picture ranging from that of beta thalassemia minor through to thalassemia intermedia to thalassemia major. Subjects homozygous for HbE (EE) are asymptomatic. |
Statements
CID11:3A51.A
0 references
dki-india-3A51.A
0 references
Concluído
0 references
13 August 2026
0 references
